Full Press Release Details
Anavex appoints Tom Skarpelos as Director
Vancouver, BC January 9, 2013 --
Anavex Life Sciences Corp. ( Anavex ) (OTCQB: AVXL) announces the appointment of
Athanasios (Tom) Skarpelos as a Director of the company effective January 9, 2013.
Tom has been actively involved in Anavex since the very
beginning, said Sean Lowry, former Director of Anavex. His passion for Anavex
and its assets, and his relationships with people and organizations close to the
company have characterized the company s development since its foundation. This
is a significant commitment on Tom s part, and we wish him well in developing
life saving treatments for serious diseases.
I am excited to be leading Anavex as we try to alleviate the
suffering of millions of people afflicted by debilitating disease, said Mr.
Skarpelos. We intend to evaluate ANAVEX 2-73 s progress in the treatment of
Alzheimer s disease, and to strategically deploy our resources to further our
business plans. As well, I look forward to expanding Anavex leadership
Mr. Skarpelos is a self-employed investor with 17 years of
experience working with private and public companies. For the past 10 years, he
has been focused on biotechnology companies involved in drug discovery and drug
development projects. Mr. Skarpelos was engaged as a consultant to Anavex Life
Sciences for one year effective August 2, 2010. His experience has led to
relationships with researchers at academic institutes in Europe and North
America. Mr. Skarpelos is a founder of Anavex Life Sciences, and is its largest
Anavex announces that Robert Chisholm has terminated his
agreement, and resigned as President, Secretary, Treasurer, Chief Financial
Officer, and as a Director of Anavex effective January 9,
2013. Effective the same date, Sean Lowry resigned as
a Director of Anavex.
About Anavex Life Sciences Corp. [ ] Anavex Life
Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the
development of novel drug candidates. ANAVEX 2-73, a drug candidate developed to
treat Alzheimer s disease through disease modification, is in human clinical
trials. Sponsored studies indicate that ANAVEX 2-73 demonstrates anti-amnesic
and neuroprotective properties, and that it is well tolerated in doses up to
55mg. Anavex is a publicly traded corporation quoted as AVXL.
Forward-Looking Statements [ ] Statements in this
press release that are not strictly historical in nature are forward-looking
statements. These statements are only predictions based on current information
and expectations and involve a number of risks and uncertainties.
Forward-looking statements in this press release include that we intend to
evaluate ANAVEX 2-73 s progress, that we intend to deploy resources in
furtherance of business plans, that we will expand our leadership team, that
ANAVEX 2-73 is in human clinical trials, and that data from a prior trial
indicates that the compound is well tolerated. Actual events or results may differ materially from
those projected in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery and development, which
include, without limitation, the potential failure of development candidates to
advance through preclinical studies or demonstrate safety and efficacy in
clinical testing and the ability to pass clinical trials so as to move on to the
next phase, our ability to finance development or satisfy the rigorous
regulatory requirements for new drugs, our ability to attract and retain quality
personnel, and that despite positive results, our competitors may offer better
or cheaper alternatives. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this cautionary
statement and Anavex Life Sciences Corp. undertakes no obligation to revise or
update this press release to reflect events or circumstances after the date
For Further Information [ ] Anavex Life Sciences Corp. [
] Research & Business Development [ ] Email: info@anavex.com
Shareholder & Media Relations [ ] Toll-free: 1-866-505-2895
[ ] Outside North America: +1 (416) 489-0092 [ ] Email: ir@anavex.com [ ] www.anavex.com